EndoForce™ Connector for Endovascular Venous Anastomosis
About Phraxis & EndoForce™
Phraxis Inc. is a Minneapolis-based medical device company advancing innovative endovascular solutions for hemodialysis access.
Our flagship product, the EndoForce™ Connector, redefines AVG creation with a minimally invasive approach, eliminating surgical dissection and promoting precise, coaxial vessel-to-graft alignment. Invented by CEO and interventional nephrologist Dr. Alex Yevzlin, EndoForce™ integrates years of clinical expertise and represents a major advancement in dialysis care.
Now FDA Approved
EndoForce™ offers a less traumatic, endovascular venous anastomosis for AVG implantation, overcoming clinical challenges of traditional sutured techniques.
Intuitive Deployment
The EndoForce™ is deployed within a peripheral vein using standard transcatheter methods and a customized easy to use Delivery System. Connection to the graft is made using standard endovascular techniques.
Extend Graft Patency
In the primary endpoint of the main investigational device exemption clinical trial, EndoForce™ demonstrated a 92% cumulative patency rate, surpassing the 80% rate associated with suture anastomosis.
Innovative Design
EndoForce™ is a patented implant designed for coaxial, endovascular anastomosis of a vein to an arteriovenous graft. Its flexible nitinol segment allows for versatile implantation angles, while a rigid segment and nitinol barbs ensure secure graft and vein attachment.
Ari Kramer, MD
Vascular Surgeon & Clinical Study Investigator
Spartanburg Regional Medical Center
“I found the device to be intelligently designed, with an intuitive implantation technique which was easy to learn and employ, reduced my operating time and facilitated both excellent and durable outcomes that outstripped our standard hand-sewn anastomoses. Overall, this is an outstanding and disruptive technology that should be welcomed in the AV access space.”
Contact Us
"*" indicates required fields